Effect of Azilsartan on Aldosterone in Postmenopausal Females

Completed · Not applicable · Has a placebo group

Conditions studied: Hypertension

In brief

The purpose of the research is to evaluate the effect of azilsartan medoximil on blood pressure and urinary aldosterone levels in postmenopausal females.

Key facts

Study ID

NCT01774591

Run by

University of Chicago

People needed

21

Starts

2013-01-01

Expected to finish

2016-01-01

Last updated by the study team

2017-11-09

Who can join

Age: 45 and older, up to 70. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female
• Ages 45-70
• Post-menopause: have not had a menstrual period for one year or more
• Diagnosed with Stage 1 hypertension
• Body Mass Index (BMI) greater than or equal to 28

You may not qualify if…

• Male
• Diagnosed with Stage 2 hypertension
• Stage 1 hypertension requiring more than one agent
• Pregnancy or attempting pregnancy
• Use of oral contraceptive pills
• Use of hormone replacement therapy
• Use of steroids
• Stage 3 or greater kidney disease
• Diabetes mellitus
• untreated hypothyroidism or hyperthyroidism
• primary hyperaldosteronism
• Cushing's disease
• obstructive sleep apnea
• chronic illness, e.g. chronic liver disease
• NYHA class III or greater heart failure
• moderate to severe lung disease

Where it is running

• University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.